Increased <scp> <i>MYBL2</i> </scp> expression in aggressive hormone‐sensitive prostate cancer
Yuki Yoshikawa(Hiroshima Prefectural Hospital), Christopher J. Sweeney(The University of Adelaide), Elai Davicioni(Coherus BioSciences (United States)), Glenn Liu(University of Wisconsin Carbone Cancer Center), Haruhito Azuma(Osaka University of Pharmaceutical Sciences), Goutam Chakraborty(National Centre for Cell Science), Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), David A. Frank(Brigham and Women's Hospital), Ying Z. Mazzu(Memorial Sloan Kettering Cancer Center), Konrad H. Stopsack(Memorial Sloan Kettering Cancer Center), Foster Burton(Dana-Farber Cancer Institute), Philip W. Kantoff(Convergent Science (United States)), Subhiksha Nandakumar(Memorial Sloan Kettering Cancer Center), Sai Harisha Rajanala(Memorial Sloan Kettering Cancer Center), Victoria Wang(Dana-Farber Cancer Institute), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Yu‐Hui Chen(Dana-Farber Cancer Institute), Rahim Hirani(New York Medical College)
Cited by 17
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k